AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca plc (NASDAQ: AZN) reported high-level results from the FoCus Phase 3 trial evaluating ALXN1840 in Wilson disease. The study met the primary goal of improving the daily mean copper mobilized from tissues over 48 weeks.

AstraZeneca's Drug Shows Promise In Copper Build-Up Genetic Disease

AstraZeneca's (AZN) phase III study evaluating ALXN1840 for Wilson disease achieves primary endpoint. The company also receives approval in Japan for Forxiga to treat chronic kidney disease.

AstraZeneca's (AZN) Rare Disease Study Meets Primary Goal

AstraZeneca PLC (LSE:AZN) announced that a phase III trial of its ALXN1840 medicine for treatment of Wilson disease has met its primary endpoint. The FoCus Phase III trial of ALXN1840 showed a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care treatments, the company said.

AstraZeneca says ALXN1840 phase III trial in Wilson disease meets primary endpoint

AstraZeneca PLC (LSE:AZN) said Forxiga (dapagliflozin), its sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in Japan for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes. The approval by Japan's Ministry of Health, Labour and Welfare follows positive results from the DAPA-CKD Phase III trial and comes after the Ministry granted Forxiga 'Priority Review' status earlier this year.

AstraZeneca's Forxiga approved in Japan for chronic kidney disease

Markets ignoring AstraZeneca's double-digit percentage growth. Investors not bullish enough on Alexion acquisition.

Why AstraZeneca Is A Buy For Dividend-Income Investors

Baidu

FinVolution Group

Himax Tech

Petroleo Brasileiro

Rio Tinto plc Sponsored

STMicroelectronics NV ADR RegS

With the S&P 500 trading near record highs, U.S. stocks are looking pricey these days. This list of international stocks could provide a better value for buy-and-hold investors.

7 Impressive International Stocks Set to Fly

Johnson & Johnson

Novavax

Hint: Pfizer, BioNTech, and Moderna didn't make the list.

3 Top COVID Vaccine Stocks That Wall Street Is Bullish About

AstraZeneca (AZN) stops the phase III CHAMPION-ALS study on Ultomiris for treating adults with amyotrophic lateral sclerosis, following a recommendation from the Independent Data Monitoring Committee.

AstraZeneca (AZN) Stops Phase III Study on Ultomiris for ALS

AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to lack of efficacy in a late-stage trial. Following an interim analysis, Alexion says it will scrap a Phase 3 study testing the long-acting C5 inhibitor Ultomiris as a treatment for amyotrophic lateral sclerosis.

Why Did AstraZeneca's Alexion Stop Amyotrophic Lateral Sclerosis Trial?

A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ: AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo. Related:   AstraZeneca's AZD7442 did not meet the primary endpoint of post-exposure prevention of symptomatic COVID-19.

AstraZeneca's COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%

Even though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost.

Here's What Recent News From the FDA Means for AstraZeneca

AstraZeneca PLC said its recently acquired Alexion unit is discontinuing a Phase III clinical trial of its Ultomiris medication in adults with amyotrophic lateral sclerosis (ALS). The drug maker said the Independent Data Monitoring Committee (IDMC) had recommended that the trial be halted due to lack of efficacy.

AstraZeneca stops phase III trial for ALS drug

AstraZeneca's treatment may offer additional protection to vulnerable groups who fail to generate a strong immune response through vaccines.

AstraZeneca's Covid-19 Antibody Therapy Effective In Preventing Symptoms Among High-Risk Groups, Trial Finds

AstraZeneca PLC (LSE:AZN) said its antibody combination AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19 in a phase III trial. AZD7442 reduced the risk of developing symptomatic COVID-19 by 77% compared to placebo, the drug company said in a statement.

AstraZeneca says antibody drug phase III trial shows significant reduction in symptomatic Covid-19

Alibaba

Barrick Gold

Netflix

Here are four underperforming stocks that look good for a strong reversal on positive fundamental developments. The post 4 Underperforming Stocks Positioned for a Strong Reversal appeared first on InvestorPlace.

4 Underperforming Stocks Positioned for a Strong Reversal

The recent decision by the EMA to approve Forxiga for the treatment of chronic kidney disease is a huge boost for the pharmaceutical company.

Here's What This Label Expansion Means for AstraZeneca Investors

AbbVie

Virtus Investment Partners

Each of these companies makes for a great vehicle to play an aging demographic.

3 Top Biotech Stocks to Buy in August

Even if you aren't crazy about the company's COVID-19 vaccine, this is still a growth investment worth considering for your portfolio.

Is AstraZeneca a Bargain Buy?

Enterprise Products Partners

Innovative Industrial Properties

With yields ranging from 2.4% to 7.9%, these fast-paced companies are perfect to fight back against rising prices.

3 High-Growth Dividend Stocks That'll Help You Crush Inflation

Following a decision to restrict the use of University of Oxford / AstraZeneca Plc's (NASDAQ: AZN) COVID-19 vaccine in those under the age of 40 years, no new cases of blood clots were found in Britain in recent weeks after receiving the jab, a study has found. The vaccine-induced immune thrombocytopenia and thrombosis (VITT) characterized by low platelet count combined with blood clots is considered a rare side effect of vector-based COVID-19 vaccines, including Astra and Johnson & Johnson (NYSE: JNJ).

Britain Study Shows Restricted Use Of AstraZeneca COVID-19 Shot Associated With No Clot Cases: Reuters

American Eagle Outfitters

American Express

Chipotle

eBay

NVIDIA

QUALCOMM

Tesla

With the trading day more than halfway over, the broad markets were somewhat mixed after the Thursday jobless claims report met estimates.

Thursday Afternoon Analyst Upgrades and Downgrades: Chipotle, eBay, Nvidia, Qualcomm, Tesla and More

Investors need to pay close attention to for AstraZeneca (AZN) stock based on the movements in the options market lately.

Do Options Traders Know Something About AstraZeneca (AZN) Stock We Don't?

A very small number of people who have been inoculated with the AstraZeneca vaccine have suffered blood clots.

Blood clots associated with AstraZeneca vaccine are ‘rare but devastating,' study says

Heavyweight broker JP Morgan Cazenove said sees around 20% “upside” to AstraZeneca PLC's (LON:AZN) current share price after it updated its analysis of the drug giant. The re-rating will occur once the merits of the recent US$39bn acquisition of Alexion start to filter through, it said in its latest note.

Are AstraZeneca shares worth buying? Read what this big hitting City broker has to say before making your call

SSR Mining

Bargains abound, even with the stock market a stone's throw from a new high.

Got $1,500? These Surefire Stocks Are Begging to Be Bought

News for AstraZeneca Stock (AZN)